Calcimimetics can reduce serum PTH, calcium, and phosphorus levels; increase BSAP; and diminish osteocalcin and the rate of parathyroidectomy in SHPT CKD patients without increasing the rate of total adverse events (321). Here, PAX5 is linked to chronic kidney disease.